F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comHealthcare Global Enterprises Ltd (HCG) is one of India’s leading cancer care specialists, offering advanced oncology treatments, multi-disciplinary healthcare services, and cutting-edge medical technology. With strong clinical infrastructure, rapid diagnostic advancements, and expansion in speciality care, the company has positioned itself well for long-term growth in the healthcare industry.
In this article, we will analyse the projected Healthcare Global Enterprises share price targets from 2025 to 2030 along with business fundamentals, valuation outlook, and investment sentiment.
| Detail | Value |
|---|---|
| Open | ₹713.35 |
| Previous Close | ₹715.95 |
| Volume | 270,039 |
| Value (Lacs) | 1,972.23 |
| VWAP | ₹715.07 |
| Beta | 0.62 |
| Market Cap (Rs. Cr.) | 10,297 |
| Day High | ₹735.00 |
| Day Low | ₹696.95 |
| UC Limit | ₹859.10 |
| LC Limit | ₹572.80 |
| 52 Week High | ₹804.65 |
| 52 Week Low | ₹456.95 |
| Face Value | ₹10 |
| All Time High | ₹804.65 |
| All Time Low | ₹62.05 |
| 20D Avg Volume | 190,200 |
| 20D Avg Delivery (%) | 77.54 |
| Book Value Per Share | ₹61.23 |
The stock is currently moving near its upper trading range, supported by strong delivery volume and increasing investor confidence.
Healthcare Global Enterprises is a specialised cancer care network with hospitals across India. The company focuses on precision oncology, robotic surgeries, and comprehensive diagnostic centres, making it one of the largest cancer care chains in the country. Backed by technology integration and treatment research, HCG is expanding the scope of cancer treatment accessibility.
India’s leading dedicated oncology healthcare chain
Multi-location hospital presence enabling strong patient reach
Advanced treatment technologies including radiation & robotics
Growing focus on clinical quality and operational performance
Increasing market demand for specialised cancer treatment
| Investor Category | Holding (%) |
|---|---|
| Promoters | 63.78% |
| Mutual Funds | 14.63% |
| Retail & Others | 14.27% |
| Other Domestic Institutions | 3.74% |
| Foreign Institutions | 3.59% |
High promoter ownership reflects strong management confidence. Mutual fund participation highlights institutional trust in long-term healthcare growth.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|
| 2025 | 780 | 860 |
| 2026 | 875 | 960 |
| 2027 | 960 | 1,075 |
| 2028 | 1,090 | 1,230 |
| 2029 | 1,240 | 1,390 |
| 2030 | 1,395 | 1,580 |
Rising demand for oncology services and expansion of cancer treatment centres may support price growth. Increased patient inflow and treatment innovation could boost revenue.
With higher occupancy and improved therapy technology, the company may expand margins, allowing investors to see stronger value appreciation.
Strategic expansion in multi-speciality care and strong treatment outcomes may enhance market valuation. Hospital network scaling could further support growth.
As India’s cancer care demand rises, HCG may gain a larger market share. Revenue from advanced clinical services may push the stock further.
Clinical expansion into new regions and improved operational efficiency could drive steady price appreciation by 2029.
By 2030, Healthcare Global Enterprises may evolve into a dominant oncology services leader with strong nationwide presence. Advancements in radiation, diagnostics, and research-based treatments could elevate long-term valuations.
Healthcare is an evergreen sector, and cancer treatment demand continues to grow in India. With a high promoter stake, increasing institutional interest, and a specialised service niche, the company offers potential for long-term growth. However, investors should track hospital utilisation metrics, clinical expansion results, and quarterly financials for informed entry.
Healthcare Global Enterprises Ltd stands as a specialized healthcare institution with strong future scalability. With steady expansion in cancer treatment and improved patient reach, the stock may achieve a target range of ₹1,395–₹1,580 by 2030. Long-term investors seeking medical sector exposure may consider HCG as a growth-oriented opportunity.
1. What is the expected share price target of HCG for 2025?
The estimated target is between ₹780 to ₹860.
2. What is the 52-week high of Healthcare Global Enterprises?
The 52-week high is ₹804.65.
3. How much promoter holding does the company have?
Promoters hold 63.78% of total shares.
4. What could be the share price of HCG in 2030?
The projected range is ₹1,395 to ₹1,580.
5. Is Healthcare Global Enterprises a good long-term investment?
With rising demand for specialised cancer care and hospital expansion, it holds long-term growth potential.
Disclaimer: This article is for informational reading only. Investors should do their own research or consult a professional before investing.
Register & Login